Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) closed up 11% on Friday after announcing solid enough first-quarter revenue from its Parkinson's disease drug Nuplazid before the bell this morning.Of course, with the share price at almost half of where it started the year at thanks to a negative CNN report in April, it shouldn't have taken much to get investors excited.Image source: Getty Images.Continue reading